Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESC 2026 | Addressing the risk of false positives with an AI-guided ATTR-CM screening model

Ilia Davarashvili • 29 Aug 2026
ESC 2026
Amyloidosis Rare Diseases

Ilia Davarashvili, MD, Leumit Health Services and Leumit Start, Tel Aviv, Israel, discusses the clinical utility and addresses the risk of false positives associated with an artificial intelligence (AI)-guided screening model for cardiac transthyretin amyloidosis (ATTR-CM), highlighting that, as a screening and assistance tool rather than a diagnostic tool, it is challenging to assess false positives or negatives directly. This interview took place during the 2026 European Society of Cardiology (ESC) Congress in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Ilia Davarashvili

Managing patients flagged as high risk for ATTR-CM: insights into the multidisciplinary approach
1:35
Managing patients flagged as high risk for ATTR-CM: insights into the multidisciplinary approach
Ilia Davarashvili • 29 Aug 2026
Exploring an AI-guided screening approach for identifying patients at high risk of cardiac ATTR
2:03
Exploring an AI-guided screening approach for identifying patients at high risk of cardiac ATTR
Ilia Davarashvili • 29 Aug 2026

Related Videos

Managing patients flagged as high risk for ATTR-CM: insights into the multidisciplinary approach
1:35
Managing patients flagged as high risk for ATTR-CM: insights into the multidisciplinary approach
Ilia Davarashvili • 29 Aug 2026
Exploring an AI-guided screening approach for identifying patients at high risk of cardiac ATTR
2:03
Exploring an AI-guided screening approach for identifying patients at high risk of cardiac ATTR
Ilia Davarashvili • 29 Aug 2026
Key priorities for achieving consistent cardiac amyloidosis care across Europe
2:00
Key priorities for achieving consistent cardiac amyloidosis care across Europe
Luuk Kieviet • 30 Aug 2026
Insights into the potential of CRISPR-based gene editing in ATTR-CM
4:07
Insights into the potential of CRISPR-based gene editing in ATTR-CM
Ronald Witteles • 29 Aug 2026
The content of VJHemOnc is intended for healthcare professionals